Jan 12, 20211 min
Updated: Jan 13, 2021
$XBI $148.06 (-0.99%) 📉
COVID:
$HGEN (+7.61%) - Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19
FINANCIALS:
$HRTX (-1.83%) - Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program
$ZNGX (-3.44%) - Zogenix Announces Preliminary, Unaudited Fourth Quarter 2020 Net Product Sales
PIPELINE:
$ADVM (+2.44%) - Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook
$CARA (+2.63%) - Initiates Phase 2 Trial of Oral KORSUVAâ„¢ for the Treatment of Pruritus in Patients with Notalgia Paresthetica
CYTK (-7.19%) - CYTOKINETICS GRANTED ORPHAN DRUG DESIGNATION FOR CK-3773274 FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
$AERI (-1.07%) - Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
$EDIT (-15.06%) - Editas Medicine Reports On Recent Progress And Outlook At J.P. Morgan Healthcare Conference & IND Acceptance
$ORIC (+1.66%) - ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones
$APVO (-3.31%) - Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
$INFI (+8.16%) - Infinity Pharmaceuticals Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial Cancer to be Presented at ASCO Genitourinary Cancers Symposium
$MGTA (+2.26%) - Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials
$ORTX (-6.28%) - Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene Therapy and Expansion of its Clinical Applications
$WVE (-6.96%) - Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications
Â